KiOmed Pharma

What we do: KiOmed Pharma is a Belgian biotechnology company specializing in the development, manufacture, and distribution of innovative medical devices based on highly pure, natural chitosan derivatives[1][2][3]. Our core expertise lies in exclusive natural chitosan chemistry, which enables us to address unmet medical needs in high-impact pathologies such as invalidating osteoarthritis, skin aging, and ophthalmology[1][2][4]. Our flagship product, KioMedine(vs)one, is a single-injection soft implant designed to relieve pain and improve mobility in patients with knee osteoarthritis, and has been launched in Europe[1][3][4]. We are committed to delivering safe, effective, and biocompatible solutions that improve the quality of life for patients worldwide, with a focus on chronic and socially burdensome conditions[1][2].

Where we are located: KiOmed Pharma is headquartered at Rue Haute Claire 4, 4041 Herstal, Belgium. Our operations are centered in the Liège region, where we leverage local talent and global partnerships to drive innovation in medical technology[1].

Short history: Founded in 2014 as a spinout from KitoZyme, KiOmed Pharma has built a strong reputation for innovation in chitosan-based medical devices[6]. The company has achieved significant milestones, including the European launch of KioMedine(vs)one and the establishment of strategic alliances for global commercialization[1][3]. KiOmed Pharma continues to expand its pipeline, targeting joint health, dermatology, and eye-related disorders, while maintaining a commitment to non-animal-derived, sustainable materials[1][2].

Organization & culture: With a team of approximately 42 employees, KiOmed Pharma fosters a collaborative, dynamic, and excellence-driven culture[1]. We value innovation, integrity, and respect, and believe that every team member plays a vital role in our mission to improve health outcomes. Our interdisciplinary teams span biotechnology, project management, and product development, creating an environment where diverse skills and ideas are celebrated[1]. We are more than a company—we are a community dedicated to research, development, and making a meaningful impact on patients’ lives.

Recent developments: In April 2024, KiOmed Pharma entered a strategic alliance with Aptissen to globally commercialize KioMedine(vs)one, enhancing patient access to this innovative treatment[1]. Additionally, the company has secured significant funding to accelerate the development of its medical solutions, and has established a licensing agreement with Hansoh Pharma for the development and commercialization of KioMedine(vs)one in China, Macau, and Taiwan, with potential milestone payments and royalties[3]. These partnerships underscore our commitment to expanding the reach and impact of our technologies.